Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial
JM Flack, R Victor, K Watson, KC Ferdinand… - Mayo Clinic …, 2008 - Elsevier
OBJECTIVE To investigate the efficacy and safety of single-pill amlodipine/atorvastatin
therapy for the simultaneous treatment of hypertension (HTN) and dyslipidemia in African …
therapy for the simultaneous treatment of hypertension (HTN) and dyslipidemia in African …
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)
Abstract The Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study
evaluated the efficacy and safety of single-pill amlodipine/atorvastatin (Caduet) for the …
evaluated the efficacy and safety of single-pill amlodipine/atorvastatin (Caduet) for the …
Amlodipine/atorvastatin single‐pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus
KC Ferdinand, JM Flack, E Saunders… - The Journal of …, 2009 - Wiley Online Library
African Americans with diabetes±the metabolic syndrome are at high risk for cardiovascular
disease. This subanalysis of the Clinical Utility of Caduet in Simultaneously Achieving Blood …
disease. This subanalysis of the Clinical Utility of Caduet in Simultaneously Achieving Blood …
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial
FH Messerli, GL Bakris, RD Ferrera… - The Journal of …, 2006 - Wiley Online Library
The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …
Single‐pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study)
R Blank, J LaSalle, R Reeves, J Maroni… - The journal of …, 2005 - Wiley Online Library
The Gemini Study was a 14‐week, open‐label, noncomparative, office‐based, multicenter
trial to evaluate single‐pill therapy in the treatment of concomitant hypertension and …
trial to evaluate single‐pill therapy in the treatment of concomitant hypertension and …
P-413: The efficacy and safety of fixed-dose combinations of amlodipine and atorvastatin in the treatment of patients with concomitant hypertension and dyslipidemia
RA Preston, P Harvey, O Herfert… - American Journal of …, 2004 - search.proquest.com
Hypertension (HTN) and dyslipidemia (DYS) commonly coexist. Patients with concurrent
HTN and DYS are at high risk of cardiovascular disease, yet most patients do not achieve …
HTN and DYS are at high risk of cardiovascular disease, yet most patients do not achieve …
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by …
FDR Hobbs, G Gensini, GBJ Mancini… - European Journal of …, 2009 - academic.oup.com
Background Single-pill amlodipine/atorvastatin targets the two most common modifiable
cardiovascular risk factors, hypertension and dyslipidaemia. We evaluated the clinical utility …
cardiovascular risk factors, hypertension and dyslipidaemia. We evaluated the clinical utility …
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease
MP Curran - Drugs, 2010 - Springer
Amlodipine/atorvastatin (Caduet®) is a single-tablet, fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia
K McKeage, MAA Siddiqui - American journal of cardiovascular drugs, 2008 - Springer
Amlodipine/atorvastatin (Caduet®) is a once-daily fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …
A randomized, placebo‐controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 …
RA Preston, P Harvey, O Herfert… - The Journal of …, 2007 - Wiley Online Library
Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …